Evaluation of health care costs and utilization patterns for patients with gout

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 640-652

  Park, Haesuk ^a   Rascati, Karen L ^a   Prasla, Karim ^b   McBayne, Tyrone ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Adherence; Gout; Gouty arthropathy; Health care costs; Retrospective studies; Serum uric acid

Indexed keywords

ALLOPURINOL; COLCHICINE; COLCHICINE PLUS PROBENECID; FEBUXOSTAT; PROBENECID; URIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; EMERGENCY CARE; FEMALE; GOUT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

COHORT STUDIES; DRUG UTILIZATION; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TEXAS; URIC ACID;

EID: 84863369464     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.020     Document Type: Article

References (23)

1. Kim K.Y., Ralph Schumacher H., Hunsche E., et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25:1593-1617.
2. Arromdee E., Michet C., Crowson C.S., et al. Epidemiology of gout: is the incidence rising?. J Rheumatol 2002, 29:2403-2406.
3. Mikuls T.R., Saag K.G. New insights into gout epidemiology. Curr Opin Rheumatol 2006, 18:199-203.
4. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63:3136-3141.
5. Brook R.A., Kleinman N.L., Patel P.A., et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006, 22:1381-1389.
6. Schlesinger N., Moore D.F., Sun J.D., Schumacher H.R. A survey of current evaluation and treatment of gout. J Rheumatol 2006, 33:2050-2052.
7. Wortmann R.L. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005, 17:319-324.
8. Sarawate C.A., Patel P.A., Schumacher H.R., et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65.
9. Wu E.Q., Patel P.A., Yu A.P., et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008, 14:164-175.
10. Halpern R., Fuldeore M.J., Mody R.R., et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009, 15:3-7.
11. Sarawate C.A., Brewer K.K., Yang W., et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925-934.
12. Riedel A.A., Nelson M., Joseph-Ridge N., et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004, 31:1575-1581.
13. Harrold L.R., Andrade S.E., Briesacher B.A., et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009, 11:R46.
14. Halpern R., Mody R.R., Fuldeore M.J., et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009, 25:1711-1719.
15. Charlson M.E., Charlson R.E., Peterson J.C., et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008, 61:1234-1240.
16. Clark D.O., Von Korff M., Saunders K., et al. A chronic disease score with empirically derived weights. Med Care 1995, 33:783-795.
17. Baser O., Palmer L., Stephenson J. The estimation power of alternative comorbidity indices. Value Health 2008, 11:946-955.
18. McHorney C.A., Victor Spain C., Alexander C.M., Simmons J. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther 2009, 31:2584-2607.
19. Martin B.C., Wiley-Exley E., Richards S., et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 2009, 43:36-44.
20. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
21. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998, 17:247-281.
22. Manning W.G., Mullahy J. Estimating log models: to transform or not to transform?. J Health Econ 2001, 20:461-494.
23. Terkeltaub R.A. Gout. N Engl J Med 2003, 349:1647-1655.